EP4704805A2 — Oral solution comprising liothyronine sodium
Assigned to Labomed Pharmaceutical Company SA · Expires 2026-03-11 · 0y expired
What this patent protects
An oral pharmaceutical solution comprising liothyronine sodium; water; at least one cosolvent selected from the group consisting of a polyol, and a glycol; and a pharmaceutically acceptable buffer; wherein the pH of the solution is from 3.5 to 6.5, and wherein the solution is obt…
USPTO Abstract
An oral pharmaceutical solution comprising liothyronine sodium; water; at least one cosolvent selected from the group consisting of a polyol, and a glycol; and a pharmaceutically acceptable buffer; wherein the pH of the solution is from 3.5 to 6.5, and wherein the solution is obtained by a process comprising the steps of i) dissolving liothyronine sodium in a carrier comprising water at a pH from 10.0 to 13.0, and ii) lowering the pH to a value from 3.5 to 6.5.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.